Pharmaceutical - GlaxoSmithKline, Boehringer Ingelheim


Popular Filters

Global asthma market to hit $18 billion by 2021 boosted by biologics

Global asthma market to hit $18 billion by 2021 boosted by biologics


The market for asthma drugs is predicted to reach $18 billion by 2021, according to new research from…

AdvairAsthmaAstraZenecaBoehringer IngelheimBreoGlaxoSmithKlineGlobalMarkets & MarketingNatasha SpillerPharmaceuticalRespiratory and PulmonaryRespiratory therapySpirivaSymbicort

Generic risk to GSK's Advair prompts buy recommendation from analysts


Pharmaceutical analysts are urging investors to buy shares of UK pharma major GlaxoSmithKline (LSE: GSK)…

AdvairAstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlinePharmaceuticalRespiratory and PulmonarySandozSpirivaSymbicort

Novel LABA/LAMA products will capture greater market share than the LABA/ICS or LAMA drug classes by 2022


The drug market for chronic obstructive pulmonary disease (COPD) therapies will see the emergence of…

AdvairAnoroBoehringer IngelheimGlaxoSmithKlineGlobalMarkets & MarketingPharmaceuticalRelvarRespiratory and PulmonarySpirivaTheravance

Pharma giants included in China's investigation into pricing of foreign imports


China's National Development and Reform Commission (NDRC) has launched an investigation into UK pharma…

Astellas PharmaBaxterBoehringer IngelheimGlaxoSmithKlineJiangsu Hengrui MedicinePharmaceuticalPricingRegulationSandozSinopharm Group

Pipeline anti-diabetic drugs could challenge market-leaders, says Datamonitor


Pipeline anti-diabetic drugs, including products from US drug major Eli Lilly (NYSE: LLY) and French…

albiglutideAmylinBoehringer IngelheimBydureonDiabetesdulaglutideEli LillyempagliflozinGlaxoSmithKlineInvokanaJohnson & JohnsonLantusNovo NordiskPharmaceuticalSanofiTresibaVictoza

New LABA/LAMA drugs set to fracture COPD market


The drug market for chronic obstructive pulmonary disease (COPD) therapies will become more fractured…

AdvairBoehringer IngelheimGlaxoSmithKlineGlobalMarkets & MarketingPfizerPharmaceuticalRespiratory and PulmonarySpiriva

Top drugmakers set up non-profit TransCelerate to speed pharma R&D


Some of the world's leading pharmaceutical companies have formed a non-profit organization to accelerate…

Abbott LaboratoriesAstraZenecaBiotechnologyBoehringer IngelheimBristol-Myers SquibbEli LillyGlaxoSmithKlineJohnson & JohnsonPfizerPharmaceuticalRegulationResearchRocheSanofiTransCelerate BioPharma

Leading dopamine agonists will continue to dominate Parkinson's market


The leading dopamine agonists, pramipexole (Boehringer Ingelheim's Mirapex/Mirapexin/Sifrol/BI-Sifrol,…

Boehringer IngelheimGlaxoSmithKlineGlobalMarkets & MarketingMirapexNeuproNeurologicalPharmaceuticalRequipRytaryUCB

UK academia-pharma collaboration attracts £14.4 million funding


In the UK, the University of Dundee and the Medical Research Council (MRC) have announced new funding…

AstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck SeronoPfizerPharmaceuticalResearch

In India, Lilly and Boehringer link for diabetes drug marketing; GSK eyeing acquisitions


The Indian subsidiaries of US drug major Eli Lilly (NYSE: LLY) and independent German pharma company…

Asia-PacificBoehringer IngelheimDiabetesEli LillyGlaxoSmithKlineMarkets & MarketingMergers & AcquisitionsPharmaceutical

Back to top